InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Explore the complete record of transactions filed by Duncan Barbara Gayle. Officer active across 3 companies, notably Halozyme Therapeutics, INC.. Aggregated, 11 filings have been published. Split: 0 buy · 2 sells. Activity tracked since 3 February 2023. The latest transaction was filed on 20 June 2025 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 条申报中的 11 条
Duncan Barbara Gayle is a declarant associated with Halozyme Therapeutics, INC. as Director, with INTERCEPT PHARMACEUTICALS INC as Chief Financial Officer, and with Atea Pharmaceuticals, Inc. as Director. The record shows 11 filings in total, and within the sampled recent filings the modal transaction nature is Attribution, with dates ranging from 2016-01-05 to 2026-06-23 and cumulative buy and sell amounts of 0.